Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of HR17031 at Different Injection Sites in Healthy Subjects
NCT06086912Phase 1Completed
- Sponsor
- Hengrui
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HR17031 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Hengrui. Primary endpoints: Area Under the Concentration-time Curve from time zero to last quantifiable concentration at Day 26, Area Under the Concentration-time Curve from time zero to infinity at Day 26 and 1 more. Started Nov 2023; status: completed.
02
Drugs
HR17031
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06086912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06086912.